Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity (PLEIO-RANK)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Spain,Spain
Call: ERC Consolidator Grant (ERC-2015-CoG, 2015)
Start date: 2016-10-01
End date: 2023-03-31
Duration (months): 78.0
Total project cost (EUR): 1999960.0
EU funding (EUR): 1164268.13
Participants: 2
Project status: SIGNED

Thousands of cancer patients worldwide are taking RANKL inhibitors for the management of bone metastasis, based on the key role of RANKL and its receptor, RANK, in osteoclasts. RANK signaling has multiple divergent effects in immunity and inflammation, both in the generation of active immune responses, as well as in the induction of tolerance. We showed that RANK overexpression induces stemness and interferes with differentiation in non transformed mammary epithelial cells and promotes mammary tumorigenesis, acting as a paracrine mediator of progesterone. However, the therapeutic potential of inhibiting RANK signaling once tumors develop and its effects on tumor immunity remain unexplored. Our proposal tackles novel concepts: Is RANK a better therapeutic target than RANKL? Does RANK induce "stemness" in other epithelia and solid tumors and how? Does RANK regulate the tumor-immune cell crosstalk? Would inhibition of RANK signaling in tumor and immune cells result in synergistic or opposing effects on tumor outcome? We hypotesize that RANK activation in solid tumors expands the cancer stem cells pool and induces an immnunosuppressive environment leading to tumor recurrence and metastasis. In PLEIO-RANK we aim to: 1. Define the contribution of RANK to the epithelial hierarchy in mammary, skin and colon, during homeostasis and tumorigenesis, undertaking lineage tracing approaches. 2. Dissect the impact of RANK loss in the epithelial or the immune compartment in tumor outcome, exploiting tissue inducible models, in breast cancer and solid tumors driven by chronic inflammation. 3. Validate the clinical implications of our findings using patient derived xenografts and human tumor samples. Based on the results of our proposal RANK inhibition could become a unique targeted therapy able to reduce metastasis and mortality in solid tumors for its pleiotropic antitumor effects in cancer stem cells, immune cells and their crosstalk.

Keywords: mammary gland development,breast cancer,tumor immunology,rank,therapy,cancer stem cells
Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES) (BRIDGES)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Preventing disease
Action type: Research and Innovation actions
Countries involved: Germany,Germany,Australia,Spain,Sweden,Sweden,France,France,United States,Netherlands,Netherlands,United Kingdom,Canada,Denmark
Call: Health promotion and disease prevention: translating 'omics' into stratified approaches (H2020-PHC-2014-two-stage, 2014)
Start date: 2015-09-01
End date: 2021-08-31
Duration (months): 72.0
Total project cost (EUR): 6460000.0
EU funding (EUR): 6200000.0
Participants: 18
Project status: CLOSED

Breast cancer affects more than 360,000 women per year in the EU and causes more than 90,000 deaths. Identification of women at high risk of the disease can lead to disease prevention through intensive screening, chemoprevention or prophylactic surgery. Breast cancer risk is determined by a combination of genetic and lifestyle risk factors. The advent of next generation sequencing has opened up the opportunity for testing in many disease genes, and diagnostic gene panel testing is being introduced in many EU countries. However, the cancer risks associated with most variants in most genes are unknown. This leads to a major problem in appropriate counselling and management of women undergoing panel testing. In this project, we aim to build a knowledge base that will allow identification of women at high-risk of breast cancer, in particular through comprehensive evaluation of DNA variants in known and suspected breast cancer genes. We will exploit the huge resources established through the Breast Cancer Association Consortium (BCAC) and ENIGMA (Evidence-based Network for the Interpretation of Germline Mutant Alleles). We will expand the existing datasets by sequencing all known breast cancer susceptibility genes in 20,000 breast cancer cases and 20,000 controls from population-based studies, and 10,000 cases from multiple case families. Sequence data will be integrated with in-silico and functional data, with data on other known risk factors, to generate a comprehensive risk model that can provide personalised risk estimates. We will develop online tools to aid the interpretation of gene variants and provide risk estimates in a user-friendly format, to help genetic counsellors and patients worldwide to make informed clinical decisions. We will evaluate the acceptability and utility of comprehensive gene panel testing in the clinical genetics context.

Keywords: breast cancer,genetic susceptibility,lifestyle risk factors,predictive testing,genetic counselling,risk modelling
Algorithmic Finance: Inquiring into the Reshaping of Financial Markets (AlgoFinance)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: The Social World and Its Diversity
Panel description: Sociology, social psychology, social anthropology, education sciences, communication studies
Countries involved: Denmark
Call: ERC Consolidator Grant (ERC-2016-COG, 2016)
Start date: 2017-05-01
End date: 2021-10-31
Duration (months): 54.0
Total project cost (EUR): 1590036.0
EU funding (EUR): 1590036.0
Participants: 1
Project status: CLOSED

Present-day financial markets are turning algorithmic, as market orders are increasingly being executed by fully automated computer algorithms, without any direct human intervention. Although algorithmic finance seems to fundamentally reshape the central dynamics in financial markets, and even though it prompts core sociological questions, it has not yet received any systematic attention. In a pioneering contribution to economic sociology and social studies of finance, ALGOFINANCE aims to understand how and with what consequences the turn to algorithms is changing financial markets. The overall concept and central contributions of ALGOFINANCE are the following: (1) on an intra-firm level, the project examines how the shift to algorithmic finance reshapes the ways in which trading firms operate, and does so by systematically and empirically investigating the reconfiguration of organizational structures and employee subjectivity; (2) on an inter-algorithmic level, it offers a ground-breaking methodology (agent-based modelling informed by qualitative data) to grasp how trading algorithms interact with one another in a fully digital space; and (3) on the level of market sociality, it proposes a novel theorization of how intra-firm and inter-algorithmic dynamics can be conceived of as introducing a particular form of sociality that is characteristic to algorithmic finance: a form of sociality-as-association heuristically analyzed as imitation. None of these three levels have received systematic attention in the state-of-the-art literature. Addressing them will significantly advance the understanding of present-day algorithmic finance in economic sociology. By contributing novel empirical, methodological, and theoretical understandings of the functioning and consequences of algorithms, ALGOFINANCE will pave the way for other research into digital sociology and the broader algorithmization of society.

Keywords: economic sociology,algorithmic finance
International NETwork for training and innovations in THErapeutic RADiation (THERADNET)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Germany,Belgium,Switzerland,France,Netherlands,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2019, 2019)
Start date: 2019-09-01
End date: 2023-12-31
Duration (months): 52.0
Total project cost (EUR): 4026324.24
EU funding (EUR): 4026324.24
Participants: 8
Project status: SIGNED

Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.

Keywords: radiobiology,combined treatment modality,tumor metabolism,radioimmunobiology,dna damage,therapeutic window,resistance mechanism tumor cell plasticity
Intelligent Glass: Affordable and Maintenance-Free Solution for Transforming Homes and Working Spaces (Intelligent Glass)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Slovenia
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-09-01
End date: 2020-02-29
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Most people spend about 90% of their days indoors, especially in cities. Vast majority of commercial and residential buildings’ windows do not transmit enough natural light to homes and offices. Reduced exposure to natural light results in Health (increased blood pressure, stress and anxiety, weaker immune system, worse sleeping cycle), and Workplace (decreased focus, reduced productivity, worse task progression, reduced energy level) issues. Increasing window surface comes with a cost. On the other side, functionality of spaces is one-sided – you can't have a shared workspace and private office in the same room, and you can't have bathroom without walls separating it from living room. Or can you? Intelligent Glass is a patentable hi-tech glass panel that turns around the way people use natural sunlight in their homes/ workspaces. It enables transparency adjusting, creating multi-functional spaces, has intelligent automation options, and cuts down energy costs. Also, its innovative in-house-built technology brings heat and UV protection, dimmability, usage as touch- or presentation screen, and allows accessible end-user price for luxurious design. The company envisages commercial and residence buildings as key targets, while also offering Intelligent Glass to internal renovations of apartments and offices. With inbound marketing serving increasing demand, outbound direct sales and industry events channels, Intelligent Glass can reach 600 clients and realize 4,4 mio EUR revenue in 5 years. Willingness to buy was already validated in projects with house builders, and individual installations on Slovenian and Croatian market. In feasibility study we want to (i) analyze further product development requirements and prepare its development plan, (ii) assess market demand, commercialization strategy and IPR protection options, and (iii) validate economic feasibility of the business model.

Keywords: smart glass,smart home,dynamic glass,pdlc technology improvement,patentable innovation,automation of sunlight management,luxury homes,smart office
8TH EUROPEAN AERONAUTICS DAYS BUCHAREST-2019 AND BERLIN-2020 (TandemAEROdays19.20)

Framework: Horizon 2020 — Societal Challenges
Programme: Smart, green and integrated transport
Action type: Coordination and support actions
Countries involved: Germany,Germany,Romania
Call: Support for dissemination events in the field of Transport Research (H2020-MG-2018-SingleStage-RTD-MOVE, 2018)
Start date: 2018-08-01
End date: 2021-01-31
Duration (months): 30.0
Total project cost (EUR): 1561530.0
EU funding (EUR): 680513.75
Participants: 4
Project status: CLOSED

The project will cover the organisation of the series of two events defined as TandemAEROdays19.20. The first event of the series will take place in Romania/Bucharest at the end of April 2019, under the EU presidency of Romania. The event will be hosted at the Palace of Parliament for three days, followed by one day with optional visits to prestigious Romanian research centres (INCAS, COMOTI) and aeronautics industries (ROMAERO, IAR Brasov, …). The second event of the series will take place in Germany/Berlin at the end of May 2020 being planned to link the AEROdays with the International Air Show ILA 2020 and the Berlin viation summit - as a marketing platform for innovation and new technologies. The event is also understood as an event to link the Croatian with the German council presidency. The TandemAEROdays19.20 is expected to attract more than 1000 visitors for both events from across Europe and world-wide, and will strongly support the aviation and aeronautics sector, both with respect to technological kowledge transfer and networking with regard to the tranport sector as a whole. The Tandem AEROdays will disseminate results and demonstrations from flagship programmes in the aviation sector, such as CleanSky, SESAR, Future Sky and will also encompass social and networking activities to stimulate future collaborations within the future FP9. Not least, the TandemAEROdays19.20 will focus on conveying successfully the message of efficient EU aeronautics R&T through relevant media channels.

Keywords: european aeronautics days,union s flagship event,dissemination of scientific results from collaborative research,europe s technological achievements and perspectives for aviation
Cooperative Au catalysis with chemically non-innocent ligands. (Au-MLC)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: France
Call: Individual Fellowships (H2020-MSCA-IF-2018, 2018)
Start date: 2019-08-01
End date: 2021-07-31
Duration (months): 24.0
Total project cost (EUR): 184707.84
EU funding (EUR): 184707.84
Participants: 1
Project status: CLOSED

Gold catalysis has gathered increasing attention from the synthetic community during the last decades, due to the remarkable ability of Au centres to promote chemical transformations. Typically, gold catalysis is based on its peculiar properties as a Lewis acid, that make it very well suited for the activation of unsaturated bonds. On the other hand, the use of gold in more sophisticated processes, such as cooperative catalysis, is at its pioneering stage, and only few examples of these strategies are currently known. Metal-Ligand Cooperation strategies (MLC) are an emerging tool in homogeneous catalysis, based on the interplay between the metal centre and the non-innocent (bifunctional) ligand. This synergy vastly enhances the performances of known transformations, and even enables new sets of reactivities. MLC has been applied to many metal centres, often with spectacular results; Au-MLC strategies, however, are unknown to date. This project focuses on the development of a family of novel Au(III) complexes bearing Brønsted basic, non-innocent pincer ligands characteristics. Their fundamental study will be performed, assessing their Lewis acidity (especially in the Pearson HSAB scale), their Brønsted basicity, and their stoichiometric interaction with X–H bonds. Based on these results, their use as bifunctional Lewis-acid catalysts will be explored for the electrophilic activation of alkynes, carbonyl compounds, and alcohols. The design and development of sequential reactions involving the bifunctional gold catalysts obtained in the context of this project will be the ultimate, most ambitious goal of this action.

Keywords: metal ligand cooperation,bifunctional catalysis,gold catalysis
Genome-wide screen of aggregation selection (Aggregation selection)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-08-01
End date: 2017-07-31
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 2
Project status: CLOSED

As protein aggregation is associated with numerous neurodegenerative diseases, several groups study the mechanism of aggregation formation and its regulation within the cell. However, besides the association with disease, some aggregates also have a functional purpose, e.g. temporary storage of hormones. This suggests that the outcome on cell fitness is determined by the relative contribution of aggregation formation, and its effect: either loss-of-function or gain-of-function. Previous genome-wide screens already identified important processes to maintain proteome stability, but none of these quantifies the origin of the aggregation effect or considers that aggregation could be beneficial for the cell. Knowledge of how each of these are regulated, is essential to obtain a complete model of the aggregation process. Recently, the host lab developed a unique method, based on a population genetics approach using yeast, that is able to simulate these toxic and beneficial effects triggered by the aggregation process. By exploiting this model using knock-out studies, I will determine the impact of each knock-out on cell fitness, quantify what is contributing to this effect (e.g. gain-of-function) and decipher how the knock-out influences the protein aggregation process. This knowledge will allow us to explore new drug targets in order to control protein aggregation.

Keywords: protein aggregation,cell fitness,deep sequencing,automated high throughput microscopy,network analysis
Biased Agonism of GPR84 as a Novel Dual Anti-inflammatory and Pro-repair Mechanism (GPR84)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-07-05
End date: 2023-07-04
Duration (months): 24.0
Total project cost (EUR): 224933.76
EU funding (EUR): 224933.76
Participants: 1
Project status: SIGNED

Elevated local and systemic inflammation has been shown to play a central role in multiple diseases. An important cellular mechanism leading to chronic increased inflammation is dysregulation of the innate immune system. A drug that modulates macrophage function, suppressing the pro-inflammatory response while maintaining pro-repair function would represent a major breakthrough in the treatment of multiple degenerative diseases. Our host group very recently identified a biased agonist of an immunometabolic receptor, GPR84, which failed to induce chemotaxis (pro-inflammatory response) while stimulating phagocytosis (pro-repair response) in both murine and human macrophage (ACS Chem. Biol. 2019). This is an important discovery of a small molecule along with a defined molecular target and cellular mechanism which, for the first time, is capable of blocking a pro-inflammatory response while stimulating a pre-repair response in both mouse and human macrophage. These results are extremely exciting and demonstrate the translational potential of our approach, but the small molecule they identified, while a useful in vitro tool which we have shared with the scientific community, cannot be progressed to in vivo proof-of-concept experiments because it is too metabolically unstable. We are therefore applying to the MSCA IF to seek medicinal chemistry support to drive a hit-to-lead project to evolve our small molecule hit into a lead candidate with appropriate properties for progression in vivo to carry out key proof-of-concept experiments in animal models of inflammation. This in vivo efficacy data will be pivotal to underpin a future funding application to support drug discovery and development campaigns.

Keywords: g protein coupled receptor gpcr,biased agonism,free fatty acids,chemotaxis,phagocytosis,inflammation,pharmacokinetics,pharmacodynamics,adme,murine,human macrophage,in vitro,in vivo